

Applicants: Bover Fuentes, et al.  
Application Serial No.: 10/539,172  
Filing Date: June 14, 2005  
Docket No.: 976-25 PCT/US  
Page 2

**AMENDMENTS TO THE SPECIFICATION**

*Please insert the sequence listing after the specification but before the listing of claims.*

*On page 10, after line 32, but before the Examples, please insert the following new paragraph:*

**--INCORPORATION OF SEQUENCE LISTING**

Incorporated herein by reference in its entirety is the Sequence Listing for the application. The Sequence Listing is disclosed on a computer-readable ASCII text file titled, “Sequence.txt”, created on December 11, 2008. The Sequence.txt file is 1 kb in size.--

*Please delete the paragraph on page 8, lines 13-17, and replace it with the following new paragraph:*

In a preferred formulation, the pharmaceutical combinations that include molecules in the A or B pools, are coupled to the immunopotentiating carrier protein by conjugation, or the formation of chimeric proteins. More particularly, inside the A molecules, GnRH analogue peptide with a sequence of pGlu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly (SEQ ID NO: 1).

Applicants: Bover Fuentes, et al.  
Application Serial No.: 10/539,172  
Filing Date: June 14, 2005  
Docket No.: 976-25 PCT/US  
Page 3

*Please delete the paragraph on page 9, lines 1-7, and replace it with the following new paragraph:*

To fulfill antibody response against GnRH, a GnRH analogue peptide, conjugated to a carrier protein (mammal immunocastration vaccine, EPO 959079), is used for immunization. The GnRH analogue peptide (pGlu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly (SEQ ID NO: 1)), and a carrier protein (a Tetanic Toxoid T-helper epitope), were chemically synthesized using two glycine residues as separators, by solid phase method and Boc/Bzl strategy, using “4-methylbenzhydrylamine” (MBH A-0.75 mmol/g, BACHEM, Swiss).